Application of New Molecular Probes in the Diagnosis and Treatment of Malignant Tumors

Dear Colleagues,

With the processive growth and aging of the population, the global incidence of cancer is gradually increasing, which continues to impose a heavy socio-economic burden to affected individuals. The advent of the era of precision medicine has brought new opportunities and challenges. Two important points to save the lives and improve the quality of life of malignant tumor patients are: 1. early diagnosis and treatment; 2. appropriate treatment plans. Molecular probes have countermeasures for both of these key points.

Molecular probes are divided into different types of probes, such as nuclear medicine, optical, magnetic, acoustic, photoacoustic, etc., which are the prerequisite and core technologies for realizing molecular imaging. In recent years, this technology has developed rapidly, and some molecular probes have been clinically transformed. The multimodal molecular imaging of tumors can detect tumors at an early stage, support clinical staging, guide the decision-making of clinical drugs and surgical treatment, and predict and evaluate the effect of cancer treatment. The growing research of some molecular probes with the integration of diagnosis and treatment not only enables the diagnosis and staging the tumor, but also provides personalized treatment for the specific target of the tumor, providing a new strategy for tumor diagnosis and treatment.

The "destructive" and "one size fits all" treatment methods of malignant tumors often cause a serious waste of medical resources and affect patient quality of life. Targeted drug specific therapy has the advantages of less trauma, less complications and good prognosis, and has gradually become a hot spot in the field of tumor therapy.

This Special Issue aims to stimulate the discussion of new developments and discoveries in the field of molecular probes for the diagnosis and treatment of malignant tumors. We welcome both reviews and research articles on topics including specific molecular probes for malignant tumor imaging, new discoveries in targeted therapy for malignant tumors, recent advances in targeted imaging and therapy for malignant tumors, and the future of molecular probe technology for malignant tumors.

I look forward to receiving your contributions.

Dr. Hui Lu
Dr. Dengfeng Cheng
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.